SPY304.32+1.35 0.45%
DIA254.29-0.06 -0.02%
IXIC9,489.87+120.88 1.29%

Why Turning Point's Stock Is Trading Higher Today

Turning Point Therapeutics (NASDAQ: TPTX) shares are trading higher on Wednesday. Wells Fargo has maintained its Overweight rating on the stock and raised its price target from $62 to $76 per share.

Benzinga · 05/13/2020 19:20

Turning Point Therapeutics (NASDAQ: TPTX) shares are trading higher on Wednesday.

Wells Fargo has maintained its Overweight rating on the stock and raised its price target from $62 to $76 per share.

Turning Point Therapeutics is a clinical-stage biopharmaceutical company involved in designing and developing molecule, targeted oncology therapies to address limitations of existing therapies.

Turning Point Therapeutics shares were up 8.08% at $56.99 at time of publication on Wednesday. The stock has a 52-week high of $67.54 and a 52-week low of $29.47.

Related Links:

Volunteers Begin Testing Moderna Coronavirus Vaccine

Gilead Reports Q1 Earnings Beat, Anticipates Short-Term Impact From Coronavirus